J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push

Johnson & Johnson (NYSE:JNJ) is reportedly preparing for a imaginable merchantability of its orthopedics unit, DePuy Synthes, arsenic it advances plans to abstracted the business.

In 2011, the medtech elephantine acquired DePuy Synthes for a monolithic $21.3 billion.

In October 2025, Johnson & Johnson said it plans to abstracted its Orthopedics concern to heighten the strategical and operational focus.

Johnson & Johnson said it is targeting completion wrong 18 to 24 months.

Don't Miss:

• Explore the Fire-Safe Energy Storage Company With $185M successful Contracted Revenue

• Before the IPO: How One Company Quietly Locked Up 500+ Iconic Character Rights

Bloomberg noted that astatine the time, CFO Joseph Wolk said the institution hadn’t yet decided however to enact the divided but said it was preparing for the anticipation of a spinoff, the astir time-consuming and resource-intensive approach. He said Johnson & Johnson was “open to ideas that others mightiness have,” including a merchantability oregon different transaction if it resulted successful greater value.

Bank of America expert wrote, “The exit makes sense, successful our view; successful the long-term, DePuy Synthes should payment from improved absorption and go much competitive.”

Buyout firms person already shown interest. Bloomberg Intelligence estimates the portion could beryllium worthy astir $20 billion, and $28 cardinal including debt.

Johnson & Johnson is presently preparing fiscal materials up of meetings with imaginable buyers successful the coming weeks, the Bloomberg study noted. Several ample backstage equity firms are reportedly considering associated bids.

See Also: Blue-chip creation has historically outpaced the S&P 500 since 1995, and fractional investing is present opening this organization plus people to mundane investors.

DePuy Synthes, which produces hep and genu replacement devices and generated $9.3 cardinal successful yearly sales, whitethorn besides pull involvement from strategical aesculapian instrumentality players.

Discussions stay preliminary, and a transaction is not assured.

Johnson & Johnson reported a fourth-quarter 2025 adjusted net of $2.46 per share, up 20.6% twelvemonth implicit year, beating the consensus of $2.44.

The institution expects 2026 income of $99.50 billion-$100.5 cardinal compared to the statement of $98.89 billion.

Read Next: 

• Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In astatine $0.85/Share

• This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors — Learn More

Image via Shutterstock

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind marketplace commercialized ideas and tools. Click present to entree unsocial insights that tin acceptable you up successful today's competitory market.